Why Exact Sciences Stock Blasted Higher on Tuesday

Core Insights - Exact Sciences experienced a notable stock performance with a nearly 4% price increase, contrasting with a 1.2% decline in the S&P 500 [1] Financial Performance - The company reported record revenue of $851 million for Q3, reflecting a robust 20% year-over-year growth, surpassing analyst expectations of less than $811 million [2] - Exact Sciences achieved a non-GAAP net income of approximately $53 million, or $0.28 per share, which was a significant surprise compared to the expected net loss of $0.03 per share [3] Future Guidance - Management raised revenue guidance for 2025 to a range of $3.22 billion to $3.24 billion, up from the previous estimate of $3.13 billion to $3.17 billion [5] - The adjusted EBITDA projection for 2025 was also increased to $470 million to $480 million, compared to the prior estimate of $455 million to $475 million [5] Product Performance - The growth in revenue and profit was attributed to the increasing popularity of key diagnostic products, Cologuard and Oncotype DX [3]